SPC Life Sciences Limited IPO Company Details:
SPC Life Sciences Limited is one of India’s leading manufacturers of advanced intermediates for certain key active pharmaceutical ingredients, including Pentoxifylline, Amiodarone HCL, Cilostazol, Trazodone, Tramadol, and Paroxetine. It is a research and development-driven chemical manufacturing company focused on chemistries involving long-chain multi-stage reactions. The advanced pharmaceutical intermediates which are manufactured by it are used in certain growing therapeutic areas including cardiovascular, vasodilator (anti-platelet), anti-psychotic, and anti-depressants, with significant market share both in India and globally for some of the products. Its customers include innovators as well as generic pharmaceutical companies, and it is registered as an approved intermediate/raw material supplier in their drug master filings with regulatory authorities, which allows it to obtain repeat business from such customers.
SPC Life Sciences Limited IPO Business Offerings:
SPC Life Sciences Limited manufactures all the key intermediates required to manufacture certain APIs.
Some of these APIs with their intermediates are as follows:
- Pentoxifylline- 6-Chloro Hexane-2-One
- Amiodarone HCL- 2-N-Butyl Benzofuran, 2-Di Ethyl Amino Ethyl Chloride Hydrochloride etc
- Trazodone- Bis (2-Chloro Ethyl) Amine Hydrochloride, 1-(3-Chlorophenyl)-4-(3-Chloropropyl) Piperazine Hydrochloride etc
- Cilostazol- 6-Hydroxy 3, 4-Di Hydro Quinoline -2(1H)-One etc
- Paroxetine- Methyl-N-Methylamido Malonate
- Tramadol- 2-Di Methyl Amino Methyl Cyclohexanone Hydrochloride
- Citalopram, Imipramine- 3-Di Methyl Amino Propyl Chloride Hydrochloride 65% Solution
Until February 2023, SPC Life Sciences Limited was operating four manufacturing blocks at a single location at Ankleshwar, Gujarat. In March 2023, the company commissioned the first phase of its new manufacturing site located at Dahej, Gujarat. It consists of an automated manufacturing block equipped with a programmable logic controller as well as common utilities, storage facilities, a quality control lab, and administrative facilities.
SPC Life Sciences Limited IPO Details:
| IPO Open Date | Not Available |
| IPO Close Date | Not Available |
| Listing Date | Not Available |
| Face Value | ₹10 per share |
| Price | Not Available |
| Lot Size | Not Available |
| Issue Size | [●]shares
(aggregating up to ₹[●]Cr) |
| Offer For Sale | 8,938,870 shares
(aggregating up to ₹[●] Cr) |
| Fresh Issue | [●]shares
(aggregating up to ₹300 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | Not more than 50% of the Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Offer |
| Retail Shares Offered | Not less than 35% of the Offer |
| Promoters | Snehal Ravjibhai Patel |
SPC Life Sciences Limited IPO
Wants To Apply Online 
SPC Life Sciences Limited IPO Financial Analysis:
| Particulars | 6M of FY-23(in cr.) | 6M of FY-22(in cr.) | FY-22(in cr.) | FY-21(in cr.) | FY-20(in cr.) | CAGR |
| Revenue from Operations | 87.91 | 69.84 | 145.64 | 132.95 | 120.93 | 9.7% |
| Other Income | 0.61 | 0.31 | 0.80 | 3.19 | 0.17 | |
| Cost of Goods Sold | 55.79 | 39.77 | 86.31 | 83.39 | 76.71 | 6.1% |
| Employee Cost | 7.70 | 7.32 | 14.47 | 12.80 | 12.08 | |
| Other expenses | 8.72 | 7.39 | 14.83 | 14.22 | 13.71 | |
| EBITDA | 16.31 | 15.67 | 30.83 | 25.74 | 18.60 | 28.7% |
| EBITDA margin% | 18.56% | 22.44% | 21.17% | 19.36% | 15.38% | |
| Depreciation | 1.30 | 1.21 | 2.48 | 1.84 | 1.60 | |
| Interest | 1.26 | 1.30 | 2.47 | 1.69 | 2.83 | |
| Profit / (loss) before tax | 13.76 | 13.16 | 25.88 | 22.22 | 14.18 | 35.1% |
| Total tax | 3.64 | 3.29 | 6.65 | 5.55 | 3.79 | |
| Profit / (loss) After-tax | 10.11 | 9.87 | 19.23 | 16.67 | 10.38 | 36.1% |
| Profit / (loss) After-tax margin% | 11.50% | 14.13% | 13.21% | 12.54% | 8.59% |
Trade AnyTime AnyWhere With Elite Empower Mobile App
Check SPC Life Sciences Limited IPO Allotment Status
Muthoot Microfin Limited IPOallotment status would be available soon after the IPO closure date. Usually the allotment comes within a week from the closing date which in this IPO yet to be announced.
One can check the allotment on the given below link with PAN number or Application number or DP Client Id. All you need to do is to follow these steps:-
-
To SPC Life Sciences Limited IPO Allotment Status
-
Go to Application Status
-
Select Valiant Laboratories IPO
-
Enter your PAN Number or Application Id or DP Client Id.
SPC Life Sciences Limited IPO
Application Form
SPC Life Sciences Limited IPO Revenue from Operations:
| Segment | 6M of FY-23(in cr.) | % | 6M of FY-22(in cr.) | % | FY-22(in cr.) | % | FY-21(in cr.) | % | FY-20(in cr.) | % | CAGR |
| Sale of products | 87.845 | 99.92% | 69.663 | 99.75% | 145.18 | 99.68% | 132.3 | 99.51% | 119.43 | 98.77% | 10.3% |
| Other Operating Revenues | 0.067 | 0.08% | 0.178 | 0.25% | 0.46 | 0.32% | 0.649 | 0.49% | 1.48 | 1.23% | -44.3% |
| Total | 87.912 | 100% | 69.841 | 100% | 145.64 | 100% | 132.949 | 100% | 120.92 | 100% | 9.7% |
SPC Life Sciences Limited IPO Major Shareholders:
| S.NO. | Name of the Shareholder | No. of Shares | % of pre-Offer shareholding |
| 1. | Snehal Ravjibhai Patel | 43,880,464 | 98.18% |
| 2. | Ravjibhai Dudabhai Dudhat | 366,944 | 0.82% |
| 3. | Sangitaben Ravjibhai Dudhat | 366,944 | 0.82% |
| 4. | Mili Snehal Patel | 77,000 | 0.17% |
| Total | 44,691,352 | 99.99% |
SPC Life Sciences Limited IPO Offer for Sale:
| S. No. | Name of the Selling Shareholder | Number of Equity Shares
being offered in the Offer for Sale (Up to) |
|
| 1. | Snehal Ravjibhai Patel | 8,938,870 Equity Shares | |
SPC Life Sciences Limited IPO Strengths:
-
SPC Life Sciences Limited has a strong and diversified portfolio of Pharma Intermediates and KSMs catering to growing therapeutic areas. It is the world’s largest manufacturer of 6-Chloro-Hexane-2-One with a 93% market share and the only supplier for 2-N-Butyl-3-(3,5-Diiodo-4-Hydroxy Benzoyl) Benzofuran.
-
SPC Life Sciences Limited has a diversified customer base with long-standing relationships across multiple geographies. It supplies to 35 customers (including international customers) across 10 countries globally. Diversification of its customer base allows it to limit its exposure to concentration risks and expand its business relationships.
-
SPC Life Sciences Limited invests in R&D activities to create a differentiating factor and sustainability vis-à-vis its competitors. This has helped it in cost optimization and the development of more intermediates in the product chain.
-
SPC Life Sciences Limited maintains a high standard of regulatory compliance and product quality systems. Its products go through various quality checks at various stages including random sampling checks and quality checks internally. Some of its key customers have audited and approved its facilities and manufacturing processes in the past, which ensures that customers are able to confirm the continuance of the quality of its facility and processes.
-
SPC Life Sciences Limited has strong sales, marketing, and distribution capabilities. Its marketing team utilizes a variety of sales and marketing techniques and programs to promote its products, including key pharmaceutical trade exhibitions such as CPHI and CHEMSPEC, advertising, and other media.
-
SPC Life Sciences Limited is led by a qualified and experienced Board of Directors, Key Managerial Personnel, and Senior Management, who have extensive knowledge and understanding of the global generic pharmaceutical business environment and have the expertise and vision to scale up its business.
SPC Life Sciences Limited IPO Risk Factors:
-
SPC Life Sciences Limited manufacturing processes involve the storage and transportation of various hazardous substances and are subject to operating risks associated with handling such hazardous materials such as the possibility for leakages and ruptures from containers, explosions, and the discharge or release of toxic or hazardous substances, which in turn may cause personal injury, property damage, and environmental contamination.
-
SPC Life Sciences Limited derives a significant part of its revenue from its major customers and it does not have long-term contracts with these customers. If one or more of such customers choose not to source their requirements from it, its business, financial condition, and results of operations may be adversely affected.
-
SPC Life Sciences Limited is subject to strict quality requirements, regular inspections, and audits by its customers, and any failure to comply with quality standards may lead to the cancellation of existing and future orders and could negatively impact its business.
-
SPC Life Sciences Limited derives a significant part of its revenue from a few products such as intermediates for Pentoxifylline and Amiodarone HCL. If its products lose favor with the customers or APIs produced using its products lose market share or favor with end users or if the company cannot protect its intellectual property regarding these products or processes, its business may be adversely affected.
SPC Life Sciences Limited IPO Prospectus:
-
SPC Life Sciences Limited IPO DRHP- https://www.sebi.gov.in/filings/public-issues/mar-2023/spc-life-sciences-limited-drhp_69567.html
- SPC Life Sciences Limited IPO RHP-
Registrar to the offer:
Link Intime India Private Limited
Tel: +91 810 811 4949
E-mail: spclifesciences.ipo@linkintime.co.in
Website: www.linkintime.co.in
Investor Grievance ID: spclifesciences.ipo@linkintime.co.in
Contact Person: Shanti Gopalkrishnan
SEBI Registration Number: INR000004058